Tafamidis versus liver transplantation as first-line therapy for hereditary transthyretin amyloidosis

P. Socie , A. B. Benmalek , A. L. Lallemand , C. C. Cauquil , F. R. Rouzet , G. L. Le Guludec , D. S. Samuel , D. A. Adams , Michel Slama (1, 2) , V. A. Algalarrondo

1 CHU Amiens-Picardie
2 MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517

Domaines: Sciences du Vivant [q-bio]

P. Socie, A. B. Benmalek, A. L. Lallemand, C. C. Cauquil, F. R. Rouzet, et al.. Tafamidis versus liver transplantation as first-line therapy for hereditary transthyretin amyloidosis. European Heart Journal, 2019, 40 (1), pp.646. ⟨hal-03584071⟩